221 related articles for article (PubMed ID: 31507617)
1. Editorial: Approaches to Advance Cancer Vaccines to Clinical Utility.
Van Nuffel AMT; Boudousquié C; Tuyaerts S
Front Immunol; 2019; 10():2032. PubMed ID: 31507617
[No Abstract] [Full Text] [Related]
2. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.
Seremet T; Brasseur F; Coulie PG
Cancer J; 2011; 17(5):325-30. PubMed ID: 21952282
[TBL] [Abstract][Full Text] [Related]
3. Personalized cancer vaccines: adjuvants are important, too.
Gouttefangeas C; Rammensee HG
Cancer Immunol Immunother; 2018 Dec; 67(12):1911-1918. PubMed ID: 29644387
[TBL] [Abstract][Full Text] [Related]
4. Cancer vaccines. Any future?
Myc LA; Gamian A; Myc A
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
[TBL] [Abstract][Full Text] [Related]
5. Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.
Goyvaerts C; Breckpot K
J Immunol Res; 2015; 2015():785634. PubMed ID: 26583156
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle delivery systems in cancer vaccines.
Krishnamachari Y; Geary SM; Lemke CD; Salem AK
Pharm Res; 2011 Feb; 28(2):215-36. PubMed ID: 20721603
[TBL] [Abstract][Full Text] [Related]
7. [Tumor vaccines-therapeutic vaccination against cancer].
Rammensee HG; Löffler MW; Walz JS; Bokemeyer C; Haen SP; Gouttefangeas C
Internist (Berl); 2020 Jul; 61(7):690-698. PubMed ID: 32462251
[TBL] [Abstract][Full Text] [Related]
8. Personalized Cancer Vaccines Advance in the Clinic.
Schmidt C
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29095978
[No Abstract] [Full Text] [Related]
9. In situ vaccination for the treatment of cancer.
Hammerich L; Bhardwaj N; Kohrt HE; Brody JD
Immunotherapy; 2016; 8(3):315-30. PubMed ID: 26860335
[TBL] [Abstract][Full Text] [Related]
10. Promises and limitations of murine models in the development of anticancer T-cell vaccines.
Lévy F; Colombetti S
Int Rev Immunol; 2006; 25(5-6):269-95. PubMed ID: 17169777
[TBL] [Abstract][Full Text] [Related]
11. How much help does a vaccine-induced T-cell response need?
Weber JS; Mulé JJ
J Clin Invest; 2001 Mar; 107(5):553-4. PubMed ID: 11238555
[No Abstract] [Full Text] [Related]
12. Immunostimulatory DNA sequences and cancer therapy.
Weiner GJ
Springer Semin Immunopathol; 2000; 22(1-2):107-16. PubMed ID: 10944805
[No Abstract] [Full Text] [Related]
13. DC-based cancer vaccines: lessons from clinical trials.
Brody JD; Engleman EG
Cytotherapy; 2004; 6(2):122-7. PubMed ID: 15203988
[No Abstract] [Full Text] [Related]
14. Guest editorial: Cancer immunology.
Yasukawa M
Int J Hematol; 2011 Mar; 93(3):261-262. PubMed ID: 21347643
[No Abstract] [Full Text] [Related]
15. Cancer vaccines.
Butterfield LH
BMJ; 2015 Apr; 350():h988. PubMed ID: 25904595
[TBL] [Abstract][Full Text] [Related]
16. Heat shock proteins (HSPs) based anti-cancer vaccines.
Ciocca DR; Cayado-Gutierrez N; Maccioni M; Cuello-Carrion FD
Curr Mol Med; 2012 Nov; 12(9):1183-97. PubMed ID: 22804241
[TBL] [Abstract][Full Text] [Related]
17. Immunization delivered by lentiviral vectors for cancer and infectious diseases.
Hu B; Tai A; Wang P
Immunol Rev; 2011 Jan; 239(1):45-61. PubMed ID: 21198664
[TBL] [Abstract][Full Text] [Related]
18. Antigen-specific vaccines for cancer treatment.
Tagliamonte M; Petrizzo A; Tornesello ML; Buonaguro FM; Buonaguro L
Hum Vaccin Immunother; 2014; 10(11):3332-46. PubMed ID: 25483639
[TBL] [Abstract][Full Text] [Related]
19. Cancer vaccines based on dendritic cells loaded with tumor-associated antigens.
Burdin N; Moingeon P
Cell Biol Toxicol; 2001; 17(2):67-75. PubMed ID: 11499697
[TBL] [Abstract][Full Text] [Related]
20. Peptide-based vaccines for cancer therapy.
Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]